Published in Brain Res on July 08, 2008
Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood (2015) 1.53
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders. J Neurochem (2010) 0.98
Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets. PLoS One (2012) 0.86
Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK. Am J Physiol Regul Integr Comp Physiol (2010) 0.85
PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia. Am J Physiol Heart Circ Physiol (2010) 0.84
Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia. Am J Physiol Heart Circ Physiol (2009) 0.82
tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK. Brain Res (2010) 0.82
Sex And Age Differences In Epinephrine Mechanisms And Outcomes After Brain Injury. J Neurotrauma (2016) 0.82
Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice. Am J Respir Cell Mol Biol (2011) 0.81
Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig. Pediatr Crit Care Med (2011) 0.81
tPA-S(481)A prevents impairment of cerebrovascular autoregulation by endogenous tPA after traumatic brain injury by upregulating p38 MAPK and inhibiting ET-1. J Neurotrauma (2013) 0.78
RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis. Transl Stroke Res (2012) 0.75
PAI-1-derived peptide EEIIMD prevents hypoxia/ischemia-induced aggravation of endothelin- and thromboxane-induced cerebrovasoconstriction. Neurocrit Care (2014) 0.75
Neonatal brain injury. N Engl J Med (2004) 5.40
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med (2001) 5.28
Cerebral sinovenous thrombosis in children. N Engl J Med (2001) 4.81
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med (1998) 4.09
MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci U S A (1999) 2.16
Basic and clinical aspects of fibrinolysis and thrombolysis. Blood (1991) 2.04
Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab (1996) 1.99
Stroke in newborn infants. Lancet Neurol (2004) 1.94
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1992) 1.88
Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin Pediatr Neurol (1998) 1.42
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science (1999) 1.37
Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab (2001) 1.37
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke (2001) 1.32
Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation (2005) 1.32
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke (2005) 1.18
Fetal thrombotic vasculopathy in the placenta: cerebral thrombi and infarcts, coagulopathies, and cerebral palsy. Hum Pathol (1999) 1.12
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors. Stroke (2000) 1.05
Alteration of MAP kinase pathways after transient forebrain ischemia. J Cereb Blood Flow Metab (2000) 1.05
Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo. FASEB J (2000) 1.04
Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood (1998) 0.97
Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood (2000) 0.95
Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood (1996) 0.95
c-Jun N-terminal kinase (JNK) and JNK interacting protein response in rat brain after transient middle cerebral artery occlusion. Neurosci Lett (2000) 0.93
Ischemia alters cerebral vascular responses to hypercapnia and acetylcholine in piglets. Pediatr Res (1989) 0.90
PTK, MAPK, and NOC/oFQ impair hypercapnic cerebrovasodilation after hypoxia/ischemia. Am J Physiol Heart Circ Physiol (2003) 0.89
NOC/oFQ and NMDA contribute to piglet hypoxic ischemic hypotensive cerebrovasodilation impairment. Pediatr Res (2002) 0.88
Postischemic cerebral microvascular responses to norepinephrine and hypotension in newborn pigs. Stroke (1989) 0.88
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Clearance of the cervical spine in clinically unevaluable trauma patients. Spine (Phila Pa 1976) (2010) 2.65
Cost-effectiveness of current treatment strategies for lumbar spinal stenosis: nonsurgical care, laminectomy, and X-STOP. J Neurosurg Spine (2010) 2.32
Is aggressive treatment of traumatic brain injury cost-effective? J Neurosurg (2012) 2.22
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Utility of delayed surgical repair of neonatal brachial plexus palsy. J Neurosurg Pediatr (2014) 1.97
Anterior surgical management of single-level cervical disc disease: a cost-effectiveness analysis. Spine (Phila Pa 1976) (2014) 1.96
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Nuclear translocation of urokinase-type plasminogen activator. Blood (2008) 1.66
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2008) 1.62
Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation (2005) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction (2012) 1.58
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood (2004) 1.50
Durability of Roux-en-Y gastric bypass surgery: a meta-regression study. Ann Surg (2012) 1.44
Decompressive hemicraniectomy for pediatric traumatic brain injury: long-term outcome based on quality of life. Pediatr Neurosurg (2011) 1.44
Geographic variation in outcomes from severe traumatic brain injury. World Neurosurg (2011) 1.44
How large is the typical subarachnoid hemorrhage? A review of current neurosurgical knowledge. World Neurosurg (2011) 1.41
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
Choosing the best operation for chronic subdural hematoma: a decision analysis. J Neurosurg (2010) 1.33
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood (2003) 1.18
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood (2002) 1.16
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
Adrenomedullin prevents sex-dependent impairment of autoregulation during hypotension after piglet brain injury through inhibition of ERK MAPK upregulation. J Neurotrauma (2010) 1.15
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J (2006) 1.12
Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem (2004) 1.12
Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost (2006) 1.12
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Endothelial expression of E-selectin is induced by the platelet-specific chemokine platelet factor 4 through LRP in an NF-kappaB-dependent manner. Blood (2004) 1.11
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
Screening tests for normal-pressure hydrocephalus: sensitivity, specificity, and cost. J Neurosurg (2006) 1.11
Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier. Am J Respir Crit Care Med (2010) 1.10
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood (2010) 1.04
Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem (2003) 1.03
Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med (2009) 1.03
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab (2009) 1.02
Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. J Biol Chem (2003) 1.02
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem (2002) 1.02
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res (2011) 1.01
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. Blood (2002) 1.01
Traumatic coagulopathy: the effect of brain injury. J Neurotrauma (2008) 1.00
The kringle stabilizes urokinase binding to the urokinase receptor. Blood (2003) 1.00
Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology (2010) 1.00